HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nitroglycerin prevents coagulopathies and foetal death associated with abnormal maternal inflammation in rats.

Abstract
Inflammation-associated foetal loss is often linked to maternal coagulopathies. Here, we characterised the role of maternal inflammation in the development of various systemic maternal coagulopathies and foetal death during mid-to-late gestation in rats. Since nitric oxide (NO) functions as an inhibitor of platelet aggregation and anti-oxidant, we also tested whether the NO mimetic nitroglycerin (glyceryl trinitrate, GTN) prevents inflammation-associated coagulopathies and foetal death. To induce chronic inflammation, pregnant Wistar rats were injected with low-doses of lipopolysaccharide (LPS; 10-40 μg/kg) on gestational days (GD) 13.5-16.5. To determine whether the effects of inflammation are mediated by tumour necrosis factor-α (TNF-α), the TNF-α inhibitor etanercept was injected on GD 13.5 and 15.5. Controls consisted of rats injected with saline. GTN was administered to LPS-treated rats via daily application of a transdermal patch on GD 12.5-16.5. Using thromboelastography (TEG), various coagulation parameters were assessed on GD 17.5; foetal viability was determined morphologically. Reference coagulation parameters were established based on TEG results obtained from control animals. LPS-treated rats exhibited distinct systemic coagulopathies: hypercoagulability, hypocoagulability, hyperfibrinolysis, and disseminated intravascular coagulation (DIC) stages I and III. A specific foetal death coagulation phenotype was observed, implicating TEG as a potential tool to identify inflammation-induced haemostatic alterations associated with pregnancy loss. Treatment with etanercept reduced the incidence of coagulopathy by 47%, while continuous delivery of GTN prevented foetal death and the inflammation-induced coagulopathies. These findings provide a rationale for investigating the use of GTN in the prevention of maternal coagulopathies and inflammation-mediated foetal death.
AuthorsTiziana Cotechini, Maha Othman, Charles H Graham
JournalThrombosis and haemostasis (Thromb Haemost) Vol. 107 Issue 5 Pg. 864-74 (May 2012) ISSN: 2567-689X [Electronic] Germany
PMID22274747 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Immunoglobulin G
  • Inflammation Mediators
  • Lipopolysaccharides
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • lipopolysaccharide, Escherichia coli O111 B4
  • Nitroglycerin
  • Etanercept
Topics
  • Administration, Cutaneous
  • Animals
  • Blood Coagulation (drug effects)
  • Blood Coagulation Disorders (blood, etiology, prevention & control)
  • Etanercept
  • Female
  • Fetal Death (blood, etiology, prevention & control)
  • Gestational Age
  • Immunoglobulin G (pharmacology)
  • Inflammation (blood, chemically induced, complications, drug therapy)
  • Inflammation Mediators (metabolism)
  • Lipopolysaccharides
  • Nitroglycerin (administration & dosage, pharmacology)
  • Phenotype
  • Pregnancy
  • Rats
  • Rats, Wistar
  • Receptors, Tumor Necrosis Factor
  • Thrombelastography
  • Time Factors
  • Transdermal Patch
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: